Russia's Rosatom signs pact with Vietnam; talks begin on power reactor project
The agreement was signed by Alexey Likhachev, Director General of
Rosatom State Corporation
, and Nguyen Manh Hung, Minister of Science and Technology of Vietnam.
As part of the cooperation, Vietnam will also participate in the Consortium 'International Research Center based on the MBIR reactor'. Rosatom will provide training support and technological assistance to develop Vietnam's nuclear research capacity.
'For decades, research has been the flagship activity of our cooperation. In the 1980s, Soviet specialists restarted a research reactor built by the Americans, and now Vietnamese specialists have ordered us a new research reactor. We have already entered the site in the south of the country, in Dong Nai province, near Ho Chi Minh City. And that is where a powerful, modern, and, presumably, the best research reactor in Southeast Asia will appear soon," said Alexey Likhachev.
He added, 'For our part, we invite our colleagues to Dimitrovgrad to conduct research on our promising multi-purpose fast reactor. In addition, this visit has marked the transition to a new stage of cooperation – the project to build a large nuclear power plant. We offer our 'bestseller' – the VVER-1200 reactor. Certainly, negotiations should take place to clarify the technical appearance and financial support. These negotiations have started today. It will certainly be a great honour and responsibility for us to build a flagship power reactor in Southeast Asia, but here we are at the very beginning of the journey.'
The roadmap builds on decades of bilateral nuclear cooperation and marks the beginning of negotiations on building a full-scale nuclear power plant using Russian VVER-1200 reactor technology.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
4 hours ago
- Mint
UCLA research frozen: $584 million grant cut stuns campus
The Trump administration has frozen $584 million in federal grants for UCLA, more than double earlier estimates, threatening hundreds of research projects. Chancellor Julio Frenk announced the massive cut Wednesday, revealing that agencies like the National Science Foundation (NSF) and National Institutes of Health (NIH) suspended funding over claims of antisemitism on campus. UCLA is the first public university targeted this way, following similar moves against private schools like Harvard and Columbia. Frenk warned the freeze would be "devastating for Americans nationwide," impacting studies on diseases, clean energy, and national security. The freeze affects 800 grants, including life-saving organ transplant research pioneered at UCLA. The cuts followed a U.S. Department of Justice report accusing UCLA of ignoring antisemitism during 2024 pro-Palestinian protests, despite the university recently paying a $6 million settlement to Jewish students over the same encampment. Federal agencies gave conflicting justifications: the NSF cited "misaligned priorities," while the Department of Energy bizarrely claimed UCLA "endangers women" by allowing transgender athletes and uses "illegal affirmative action" in admissions. UC President James Milliken slammed the move, stating: "These cuts do nothing to address antisemitism" and would be a "death knell" for medical and scientific breakthroughs. UCLA has created a safety office and antisemitism task force since the protests. Under pressure, the University of California agreed to negotiate with the Trump administration before a September 2 lawsuit deadline . The talks aim to restore funding, but precedents are worrying: Columbia paid $200 million and Brown University paid $50 million to regain their grants. Over 3,000 UCLA staff attended an emergency town hall Monday, with Vice Chancellor Roger Wakimoto warning that researchers can't even access existing funds for critical work . Frenk, whose family fled Nazi Germany, stressed UCLA's reforms but called the freeze a "cruel manipulation" unrelated to fighting hate . California Governor Gavin Newsom blasted Trump for 'weaponizing Jewish students' pain'. Organ transplant technology keeping lungs "breathing" outside bodies Asteroid-tracking systems guarding Earth from space threats Valley fever treatment research for the deadly disease Faculty warn the freeze could cancel decades of progress, like UCLA's role in creating the internet . With Columbia's settlement as a template, UCLA faces tough choices: pay massive fines or risk permanent cuts. "Every deal made makes it harder for others to resist," warned American Association of University Professors director Mia McIver . As UC negotiates, scientists statewide brace for ripple effects, hoping lifesaving work won't become collateral in a political war .
Economic Times
5 hours ago
- Economic Times
Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up
Synopsis Novo Nordisk warned of ongoing competition from copycat versions of its obesity drug Wegovy and signaled possible layoffs due to slowing sales growth, especially in the U.S. The Danish drugmaker, which lost $95 billion in market value after cutting full-year forecasts, said over one million Americans still use compounded GLP-1 drugs despite a U.S. ban. Reuters Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli Lilly, the Danish drugmaker warned on Wednesday. Novo, which became Europe's most valuable company worth $650 billion last year on booming sales of Wegovy, is facing a pivotal moment as the medicine loses market share and sees sales growth slow, especially in the United States. It has warned of far slower growth this year - in part due to compounders who have been allowed to make copycat medicines based on the same ingredients as Wegovy due to shortages. Novo cut its full-year sales and profit forecasts last week, wiping $95 billion off its market value since. The shares were down 3.4% at 1350 GMT. The slide is a huge and abrupt turnaround for the firm that has been one of the world's hottest investment stories, which led to a rapid expansion of manufacturing and sales capacity. Now the firm is eyeing potential cost-cutting measures. "We probably won't be able to avoid layoffs," outgoing CEO Lars Fruergaard Jorgensen told Danish broadcaster DR. "When you have to adjust a company, there are some areas where you have to have fewer people, some (areas) where you have to be smaller." He added, though, that any decision on layoffs would be in the hands of the incoming CEO, company veteran Maziar Mike Doustdar, who takes over on Thursday. On a media call, Jorgensen said the market for copycat versions of Wegovy's class of drugs - known as GLP-1 receptor agonists - was of "equal size to our business" and compounded versions of Wegovy were sold at a "much lower price point". In May, the company said it expected many of the roughly one million U.S. patients using compounded GLP-1 drugs to switch to branded treatments after a U.S. Food and Drug Administration ban on compounded copies of Wegovy took effect on May 22, and it expected compounding to wind down in the third quarter. However, finance chief Karsten Munk Knudsen said on Wednesday that more than one million U.S. patients were still using compounded GLP-1s and that Novo's lowered outlook has "not assumed a reduction in compounding" this year. "The obesity market is volatile," Knudsen told analysts when asked under what circumstances the company could see negative growth in the last six months of the year. The low end of Novo's new full-year guidance range would be for "unforeseen events", such as stronger pricing pressure in the U.S. than forecast, he said. The lower end of the range would imply sales around 150 billion Danish crowns ($23 billion) in the second half of 2025, compared with 157 billion in the same period last year. ENCOURAGING PRESCRIPTION DATA Knudsen reiterated that the company was pursuing multiple strategies, including lawsuits against compounding pharmacies, to halt unlawful mass compounding. Jorgensen said the company was encouraged by the latest U.S. prescription data for Wegovy. While the drug was overtaken earlier this year by rival Lilly's Zepbound in terms of U.S. prescriptions, that lead has narrowed in the past month. Second-quarter sales of Wegovy rose by 36% in the U.S. and more than quadrupled in markets outside the U.S. compared to a year ago, Novo said. While Wegovy's U.S. pricing held steady in the quarter, the company expected deeper erosion in the key U.S. market in the second half, due to a greater portion of sales expected from the direct-to-consumer or cash-pay channel, as well as higher rebates and discounts to insurers, Knudsen said. He said Novo was expanding its U.S. direct-to-consumer platform, NovoCare, launched in March, and may need to pursue similar "cash sales" directly to patients, outside of insurance channels, in some markets outside the United States. COST CUTS The company reiterated its full-year earnings expectations on Wednesday after last week's profit warning. Jorgensen said Novo was acting to "ensure efficiencies in our cost base" as the company announced it would terminate eight R&D projects. "There seems to be a larger R&D clean-out than usual, but we do not know if this reflects a strategic re-assessment or just a coincidence," Jefferies analysts said in a note. Investors have questioned whether Novo can stay competitive in the booming weight-loss drug market. Several equity analysts have cut their price targets and recommendation on the stock since last week. Shares in Novo plunged 30% last week - their worst weekly performance in over two decades. Sales rose 18% in the second quarter to 76.86 billion Danish crowns, below analysts' initial expectations.
India Today
6 hours ago
- India Today
Trump administration sanctions Mexican rapper over allegations of cartel ties
The Trump administration announced on Wednesday that it was sanctioning Mexican musician Ricardo Hernndez, known as 'El Makabelico,' over allegations that the artist was laundering money for a drug move comes after the administration stripped the visas of some of Mexico's most famous musicians, targeting those whose genres often explore themes related to US Treasury Department has taken action against the musician who is also identified as a "narco-rapper," for his alleged ties to the Cartel del Noreste (CDN), which evolved from the Zetas Cartel. The musician, named Hernndez, is accused of laundering money for the criminal organisation through his concerts and events. The CDN is among several Latin American crime groups designated as foreign terrorist organisations by the Trump According to the Treasury Department's allegations, Hernndez has been sanctioned because he is believed to be acting for or on behalf of the CDN. The department claims that half of his streaming royalties are funnelled directly to the cartel. The sanctions also extend to leaders of the has however, not been an official response from the rapper about the sanctions imposed on FROM THE TREASURY DEPARTMENT'CDN depends on these alternative revenue streams and money laundering methods to boost their criminal enterprise, diversifying their income beyond criminal activity like drug trafficking, human smuggling, and extortion," wrote the Treasury Department in a news release."The Treasury Department will continue to be relentless in its effort to put America First by targeting terrorist drug cartels. These cartels poison Americans with fentanyl and conduct human smuggling operations along our southwest border," said U.S. Treasury Secretary Scott US Treasury Department also took it to their social media handle on X to announce the sanctions on the rapper along with three high-ranking members of the Treasury's Office of Foreign Assets Control sanctioned three high-ranking members of the Mexico-based terrorist organization Cartel del Noreste (CDN), along with narco-rapper El narco-rapper's concerts and events are used to launder money on behalf of CDN,— Treasury Department (@USTreasury) August 6, 2025THE SANCTIONThe sanctions imposed will result in blocking the rapper's properties in US and freeze financial transactions with any businesses owned by those sanctioned, and threaten secondary sanctions against foreign financial institutions that do business with recent years, emerging artists like Peso Pluma have propelled Mexican music genres onto the global stage by blending traditional sounds with trap and other contemporary influences, rivalling international stars such as Taylor Swift and Bad Bunny on streaming genres — particularly 'narco-corridos' — have sparked much controversy, as many performers reference drug cartels and the broader 'narco culture.' While some tracks glorify criminal figures, others reflect the difficult realities faced by youth in cartel-dominated regions, drawing parallels to themes often explored in American style of music has been at the heart of ongoing debates over the boundaries between free artistic expression and censorship, with several Mexican states previously prohibiting live performances of certain ADMINISTRATION'S PREVIOUS STEPSadvertisementIn recent months, the Trump administration has taken action by revoking visas for several artists associated with the genre. In May, the well-known northern Mexican group Grupo Firme, which has worked to move away from cartel-related content, announced the cancellation of a planned California concert due to visa April, the administration said it was revoking the visas of the band Alegres de Barranco after they flashed the face of a cartel boss behind them at a concert, prompting a controversy and even criminal investigations in Mexico.- EndsWith inputs from agencies
